Bio-Rad rallies 13.9% as activist stake speculation lifts shares

Bio-Rad Laboratories (BIO) is up 13.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The jump appears tied to market chatter that an activist investor has built a sizeable position and may push for steps to improve shareholder value. A key focus for investors is Bio-Rad’s large equity stake in Sartorius, which has recently driven headline earnings volatility and could be viewed as a potential value-unlock lever.

Details:

Trading interest increased after reports that a prominent activist investor has taken a sizeable stake in Bio-Rad and intends to press for actions to boost the stock.

Those reports also pointed to the activist building a position in Sartorius, where Bio-Rad is an investor, bringing renewed attention to Bio-Rad’s look-through value and strategic options tied to that holding.

In Bio-Rad’s April 30, 2026 quarterly update, the company posted a GAAP net loss largely driven by changes in the fair value of its Sartorius investment, underscoring how material that stake is to headline results.

The same update included lowered full-year 2026 non-GAAP, currency-neutral revenue and operating-margin expectations, which may have set the stage for an “activist catalyst” re-rating despite the softer outlook.

Sources:

Wall Street Journal, Bio-Rad Investor Relations (Business Wire), Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive BIO Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BIO Hedge Fund Activity

We have seen 191 institutional investors add shares of $BIO stock to their portfolio, and 198 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VERITAS ASSET MANAGEMENT LLP removed 543,335 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $151,454,631
CAPITAL WORLD INVESTORS added 450,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $125,437,500
FULLER & THALER ASSET MANAGEMENT, INC. removed 259,577 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $72,357,088
BARCLAYS PLC added 254,341 shares (+1038.4%) to their portfolio in Q1 2026, for an estimated $70,897,553
BOSTON PARTNERS removed 239,419 shares (-96.7%) from their portfolio in Q1 2026, for an estimated $66,738,046
NOMURA HOLDINGS INC added 217,342 shares (+inf%) to their portfolio in Q1 2026, for an estimated $60,584,082
WESTFIELD CAPITAL MANAGEMENT CO LP removed 165,107 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $46,023,576

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$BIO Government Contracts

We have seen $4,327,707 of award payments to $BIO over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

LYPHOCHEK WHOLE BLOOD METALS CONTROL - QUALITY CONTROL REAGENTS: $405,324
SEROLOGICAL AUTOMATED ANALYZERS FOR HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C VIRUS TESTING FOR MILITARY...: $349,963
CONSUMABLES AND REAGENT PRODUCTS FOR SEROLOGICAL AUTOMATED ANALYZER SYSTEMS.: $244,260
IMMUNOLOGY: $235,226
BIOPLEX REAGENTS AND CONSUMABLES: $200,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$BIO Price Targets

Multiple analysts have issued price targets for $BIO recently. We have seen 3 analysts offer price targets for $BIO in the last 6 months, with a median target of $300.0.

Here are some recent targets:

Dan Leonard from RBC Capital set a target price of $320.0 on 05/15/2026
Brandon Couillard from Wells Fargo set a target price of $290.0 on 05/01/2026
Patrick Donnelly from Citigroup set a target price of $300.0 on 04/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.